Showing 2671-2680 of 5621 results for "".
- Alexander van der Mey Named New CCO at Optimo Medical AGhttps://modernod.com/news/alexander-van-der-mey-named-new-cco-at-optimo-medical-ag/2477248/As of January 16, Alexander van der Mey assumed the role of chief commercial officer (CCO) position of Optimo Medical AG. In his new position, Mr. van der Mey is responsible for global marketing and sales. Mr. Van der Mey has studied business administration in Germany and the Netherlands.
- AOA Receives Department of Justice Approval to Expand Group Purchasing Activities for Its AOAExcel Membershttps://modernod.com/news/aoa-receives-department-of-justice-approval-to-expand-group-purchasing-activities-for-its-aoaexcel-members/2477244/The Department of Justice (DOJ) announced January 15 that it will not challenge a proposal by the American Optometric Association to expand its group purchasing organization’s (GPO) activities to include the purchase of optometric products for resale to consumers, specifically eyeglass lenses, fr
- Genentech/Roche Initiate First Diabetic Macular Edema Phase 3 Trial of the Port Delivery System with Ranibizumabhttps://modernod.com/news/genentech-roche-initiate-first-diabetic-macular-edema-phase-3-trial-of-the-port-delivery-system-with-ranibizumab/2477233/Genentech and Roche have initiated a new phase 3 clinical trial investigating the Port Delivery System with ranibizumab (PDS) in people with diabetic macular edema (DME). The PDS is an investigational first-of-its-kind refillable eye implant designed to continuously release a customized formulati
- Exonate Announces Collaboration With Janssen to Develop a New Eye Drop for the Treatment of Retinal Vascular Diseaseshttps://modernod.com/news/exonate-announces-collaboration-with-janssen-to-develop-a-new-eye-drop-for-the-treatment-of-retinal-vascular-diseases/2477223/Exonate, an early stage biotechnology company, announced that it has entered into a strategic collaboration agreement with Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. Through the collaboration, Exonate will work with Janssen Research & Development scientists to develop an
- Watchdog: NHS Delays Responsible for Glaucoma Patients Going Blindhttps://modernod.com/news/watchdog-nhs-delays-responsible-for-glaucoma-patients-going-blind/2477221/Long delays to treatment on the NHS have been responsible for glaucoma patients losing their sight, a safety watchdog in the UK has warned, according to a report in Independent. The
- US Cancer Death Rates Are Dropping at the Fastest Pace on Recordhttps://modernod.com/news/us-cancer-death-rates-are-dropping-at-the-fastest-pace-on-record/2477215/The cancer death rate in the U.S. fell by the most on record as advances in treatments for lung tumors like video-assisted surgery helped prolong the lives of patients, according to a Bloomberg
- Acucela Announces Publication Assessing the Role of Emixustat Hydrochloride in Retinal Degeneration Treatmenthttps://modernod.com/news/acucela-announces-publication-assessing-the-role-of-emixustat-hydrochloride-in-retinal-degeneration-treatment/2477209/Acucela announced the publication of an article concerning the company’s investigational drug candidate, emixustat hydrochloride (emixustat), in the scientific journal Drug Discovery Today. The published article, “Pharmacotherapy for Metabolic and Cellular Stress in Degenerative R
- Market Scope: Ophthalmic Deals Surge in 2018-2019; Most Transactions Involve New Ventureshttps://modernod.com/news/market-scope-ophthalmic-deals-surge-in-2018-2019-most-transactions-involve-new-ventures/2477195/Ophthalmic deals garnered over $9 billion from January 2018 through October 2019, driven largely by dry eye and retina related fundraising. Over 100 transactions occurred during this period, and over 80 percent of transaction are categorized as new ventures. The Novartis acquisition of Xii
- With EyeCare Partners Deal, Swiss Firm Sees a Base for ‘Organic Growth, Expansion and Consolidation’ of U.S. Vision Markethttps://modernod.com/news/with-eyecare-partners-deal-swiss-firm-sees-a-base-for-organic-growth-expansion-and-consolidation-of-u-s-vision-market/2477176/In the second major acquisition of an eyecare practice management group this year, the Switzerland-based Partners Group announced Monday morning that it has agreed to make a significant investment in EyeCare Partners LLC (ECP). FFL Partners announced separately that it was selling the stake it ha
- Bausch + Lomb Initiates Clinical Trial Evaluating New Cohesive Ophthalmic Viscosurgical Device (OVD)https://modernod.com/news/bausch-lomb-initiates-clinical-trial-evaluating-new-cohesive-ophthalmic-viscosurgical-device-ovd/2477174/Bausch + Lomb announced that it has initiated a clinical trial evaluating the safety and efficacy of a new cohesive ophthalmic viscosurgical device (OVD) intended to provide surgeons with a new option in the continuum of cohesive and dispersive viscoelastics. “This is the second new OVD th